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Abstract Ghrelin is a novel growth hormone-releasing peptide
with a unique acylated structure. Here we reveal that prepro-
ghrelin gene is expressed in the mouse kidney and glomerulus.
We also show by reverse-phase high performance liquid
chromatography coupled with radioimmunoassay that the mouse
kidney does produce ghrelin. The ghrelin immunoreactivity in the
mouse kidney is 6.79 þ 0.48 fmol/mg (n = 5), which is much more
abundant than that in the mouse plasma of 0.339 þ 0.029 fmol/Wl
(n = 6). Furthermore, prepro-ghrelin gene is expressed in cultured
rat mesangial cells, fibroblast-like NRK-49F cells and mouse
podocytes, but not in rat epithelial cell-like NRK-52E cells.
Ghrelin receptor gene is also expressed in the rat kidney. These
findings demonstrate that the kidney, glomerulus and renal cells
express prepro-ghrelin gene and ghrelin is produced locally in the
kidney, and suggest the endocrine and/or paracrine roles of
ghrelin in the kidney. ß 2000 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Growth hormone (GH) and insulin-like growth factors
(IGFs) play a number of important physiological and patho-
physiological roles in the kidney [1]. GH stimulates IGF-1
secretion from the liver, and both GH and IGF-1 increase
renal blood £ow, glomerular ¢ltration rate, tubular phosphate
reabsorption, and possibly tubular sodium reabsorption [1^6].
They are also involved in normal kidney growth as well as
renal hypertrophy observed in nephrectomy and diabetes
[1,7,8]. Ghrelin is a novel 28 amino acid peptide with an O-
n-octanoyl (C7H15CO) moiety, which has potent activity to
stimulate GH release from the pituitary gland in rats and
humans [9,10]. The unique modi¢cation in ghrelin peptide,
or acylation, is essential for its biological action. This kind
of modi¢cation for peptides has never been reported, suggest-
ing the presence of a novel mechanism for post-translational
modi¢cation [1]. Ghrelin was identi¢ed in the stomach as an
endogenous ligand for an orphan receptor which has so far
been called GH secretagogue (GHS) receptor [11,12]. Prepro-
ghrelin gene is expressed in the oxyntic gland of the stomach
and the arcuate nucleus of the hypothalamus, but its expres-
sion in other tissues is not well understood [9]. Whether acyl-
ation of ghrelin peptide occurs speci¢cally in the stomach
also remains unknown. Furthermore, actions of ghrelin except
for stimulation of GH secretion have been implied based upon
studies on the actions of GHS and the distribution of GHS
receptor [9,13^15]. In the present study, we investigated pre-
pro-ghrelin gene expression in the kidney, glomerulus and
kidney-derived cultured cells, and also the gene expression
of its receptor, GHS receptor, in the kidney. We also exam-
ined whether the kidney produces ghrelin.
2. Materials and methods
2.1. Animals
Kidneys and blood were collected from adult C57BL/6 mice (Shi-
mizu Laboratory Supplies, Kyoto, Japan) and adult Wistar-Kyoto
rats (Shionogi Research Laboratories, Osaka, Japan) under anesthesia
with diethyl ether (Nacalai Tesque, Kyoto, Japan). Glomeruli were
isolated from kidney cortices by the di¡erential sieving method [16].
2.2. Kidney and blood samples for radioimmunoassay (RIA)
For peptide extraction, mouse kidneys were boiled for 5 min in
10-fold volume of water to inactivate intrinsic proteases, adjusted to
1 M acetic acid/20 mM HCl after cooling, and homogenized with
Polytron mixer (Kinematica GmbH Kriens, Luzern, Switzerland).
The supernatant obtained after 30 min centrifugation at 11 000 rpm
was loaded onto Sep-Pak C18 cartridge (Waters, Milford, MA, USA),
which was pre-equilibrated with 0.1% tri£uoroacetic acid (TFA). The
cartridge was washed with 5% CH3CN/0.1% TFA and eluted with
60% CH3CN/0.1% TFA. The eluate was lyophilized and subjected
to RIA for ghrelin.
Whole blood samples were collected with 2 mg/ml EDTA-2Na
(Nacalai Tesque) and 500 KIU/ml aprotinin (Wako, Osaka, Japan).
Plasma was diluted with an equal volume of 0.9% saline before load-
ing onto Sep-Pak C18 cartridge.
2.3. RIA for ghrelin
Two kinds of polyclonal antibodies were raised against the carbox-
yl- (Gln13^Arg28) and amino-terminal fragments (Gly1^Lys11 with O-
n-octanoylation at Ser3) of rat ghrelin in rabbits as previously de-
scribed [9,17]. Mouse ghrelin has a completely identical structure
with rat ghrelin (manuscript submitted). Ghrelin and its fragments
were ¢rst synthesized as fully protected peptides by a peptide synthe-
sizer (433A, Applied Biosystems, Foster City, CA, USA), and further
acylated with n-octanoic acid at Ser3 as previously reported [9]. RIA
was carried out in duplicate at 4‡C. Each RIA incubation mixture was
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composed of 100 Wl of standard ghrelin or unknown sample and 200 Wl
of antiserum diluted with RIA bu¡er (50 mM sodium phosphate bu¡-
er (pH 7.4), 0.5% bovine serum albumin, 0.5% Triton X-100, 80 mM
NaCl, 25 mM EDTA-2Na and 0.05% NaN3) containing 0.5% normal
rabbit serum. Two antisera recognizing the carboxyl- and amino-ter-
mini of ghrelin were used at ¢nal dilutions of 1:20 000 and
1:6 000 000, respectively. After incubation for 12 h, 100 Wl of 125I-
labeled tracer (15 000 cpm) was added. After an additional 36 h in-
cubation, 100 Wl of anti-rabbit IgG goat serum was added and further
incubated for 24 h. Free and bound tracers were separated by centri-
fugation at 3000 rpm for 30 min. The radioactivity in the pellet was
counted with a gamma counter (ARC-600, Aloka, Tokyo, Japan).
2.4. Reverse-phase high performance liquid chromatography
(RP-HPLC) coupled with RIA
Peptide extract from mouse kidneys (20 mg wet tissue) was loaded
onto Sep-Pak C18 cartridge and eluate was fractionated by RP-HPLC
on WBondasphere C18 (3.9U150 mm, Waters) as previously described
[9]. Solvent system was a linear gradient of CH3CN from 10% to 60%
in 0.1% TFA for 40 min and £ow rate was 1 ml/min. An aliquot of
each fraction (0.5 ml) was lyophilized and subjected to RIA for ghre-
lin.
2.5. Cell culture
Establishment of cultured mesangial cells from rat glomeruli has
been described elsewhere [16]. Normal rat kidney-derived NRK-52E
and NRK-49F cells were obtained from American Type Culture Col-
lection (Rockville, MD, USA). A conditionally immortalized mouse
podocyte clone, MPC-5, was kindly provided by Dr. Peter Mundel
(Albert Einstein College of Medicine, NY, USA) [18]. Podocytes were
cultured either with 10 U/ml mouse recombinant Q-interferon (Gibco
BRL, Grand Island, NY, USA) at 33‡C (permissive condition) or
without Q-interferon at 37‡C (non-permissive condition). Mesangial
cells, NRK-52E, and NRK-49F were grown in Dulbecco’s modi¢ed
Eagle’s medium (Gibco BRL) and podocytes in RPMI 1640 (Nihon-
seiyaku, Tokyo, Japan), both with 10% fetal calf serum (Gibco BRL).
2.6. Reverse transcription (RT)-PCR for prepro-ghrelin gene
expression
Total RNA was extracted from tissues and cells using TRIzol re-
agent (Gibco BRL) as described previously [19]. RT-PCR was per-
formed with oligo (dT)15 primer, SuperScript II reverse transcriptase
(Gibco BRL), and rTaq (Takara, Tokyo, Japan). The following prim-
ers were used: mouse prepro-ghrelin sense, 5P-AGCATGCTCTG-
GATGGACATG-3P (nucleotides (nt) 55^75) (manuscript submitted);
mouse prepro-ghrelin antisense, 5P-AGGCCTGTCCGTGGTTA-
CTTGT-3P (nt 383^362); rat prepro-ghrelin sense, 5P-TTGAGCCCA-
GAGCACCAGAAA-3P (nt 112^132) [9] ; rat prepro-ghrelin antisense,
5P-AGTTGCAGAGGAGGCAGAAGCT-3P (nt 458^437); L-actin
sense, 5P-AACGAGCGCTTCCGCTGTCC-3P (nt 754^773) [20]; L-
actin antisense, 5P-AATCTTGATCTTCATGGTGC-3P (nt 987^968).
The annealing temperature was 60‡C and cycles of PCR were 40 for
ghrelin and 30 for L-actin. In the case of rat prepro-ghrelin, Southern
blot hybridization was performed as previously described with 5P-end
labeled internal oligonucleotide probe, 5P-AAAGGAATCCAA-
GAAGCCACCAGC-3P (nt 144^167) [9,21]. Speci¢cities of the prod-
ucts were con¢rmed by direct sequencing with BigDye Terminator
cycle sequencing kit FS and 310 Genetic Analyzer (Applied Biosys-
tems).
2.7. RT-PCR for ghrelin receptor gene expression
As the receptor for ghrelin, we examined rat GHS receptor type 1a
[9,12]. The following primers were used: sense, 5P-GCTGAGCGTC-
GAGCGCTACTTCG-3P (nt 405^427); antisense, 5P-GTTGCAG-
TACTGGCTGATCTGAGC-3P (nt 2943^2920). The reaction pro¢le
was identical with that of ghrelin.
3. Results
3.1. Prepro-ghrelin gene expression in the kidney and
glomerulus
By use of RT-PCR, we examined prepro-ghrelin gene ex-
pression in the mouse kidney and glomerulus. The prepro-
ghrelin cDNA, 329 bp in size, was ampli¢ed both in the kid-
ney and glomerulus (Fig. 1). L-Actin cDNA, 234 bp in size,
was also ampli¢ed to verify that reverse transcription was
successfully done for all materials. In negative control experi-
ments, where all the procedures were similar except that re-
verse transcriptase was omitted, no bands were observed.
These ¢ndings prompt us to examine the content of ghrelin
in the kidney.
3.2. Detection of ghrelin in the kidney and blood
By RIA using an antiserum recognizing both the carboxyl-
termini of ghrelin and the desacyl peptide, carboxyl-terminal
ghrelin immunoreactivity (C-IR) in the mouse kidney extract
was measured as 6.79 þ 0.48 fmol/mg wet tissue (mean þ
S.E.M., n = 5). The amino-terminal ghrelin immunoreactivity
(N-IR), which was assayed using another antiserum speci¢c
for the amino-terminus of ghrelin but not for the desacyl
peptide, was 0.282 þ 0.074 fmol/mg wet tissue (n = 5). To fur-
ther analyze the speci¢city of these ghrelin immunoreactiv-
ities, we fractionated the kidney extract by RP-HPLC and
measured ghrelin immunoreactivities again (Fig. 2). C-IR
was eluted as a major peak with a retention time of 13 min
by 13.2 fmol/fraction, which was identical with the elution
position of synthetic desacyl ghrelin [9]. The major peak of
N-IR appeared with a retention time of 22 min by 1.3 fmol/
fraction, which co-migrated with synthetic ghrelin. These ¢nd-
ings con¢rmed the speci¢city of C-IR and N-IR in the mouse
kidney. The minor peak of N-IR with a retention time of 24
min might correspond to an unidenti¢ed form of ghrelin. We
also examined ghrelin concentration in the mouse plasma and
found that C-IR and N-IR were 339 þ 29 and 6.80 þ 1.00
fmol/ml, respectively (n = 6). These ¢ndings indicated that
the mouse kidney and plasma contain both ghrelin and the
desacyl peptide, the desacyl peptide predominates ghrelin, and
the ghrelin content in the kidney is much more abundant than
that in the plasma.
3.3. Prepro-ghrelin gene expression in cultured renal cells
We next investigated prepro-ghrelin gene expression in kid-
ney-derived cultured cells. We examined rat mesangial cells,
non-glomerular epithelial cell-like NRK-52E cells and ¢bro-
blast-like NRK-49F cells. Rat prepro-ghrelin cDNA, 347 bp
in size, was ampli¢ed in mesangial cells and NRK-49F cells,
but not in NRK-52E cells (Fig. 3). We further examined
mouse podocytes. In permissive conditions these cells exhibit
cobblestone-like appearances corresponding to undi¡erenti-
Fig. 1. Prepro-ghrelin gene expression in mouse kidney, glomerulus,
and podocyte. RT + and 3, with and without reverse transcription.
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ated status, whereas in non-permissive conditions they show
arborized shapes corresponding to di¡erentiated or physio-
logic status [18]. Podocytes in non-permissive conditions as
well as in permissive conditions expressed prepro-ghrelin
gene (Fig. 1).
3.4. Ghrelin receptor gene expression in the kidney
Ghrelin receptor (or GHS receptor) cDNA, 511 bp in size,
was ampli¢ed in the rat kidney (Fig. 4). The ampli¢cation was
observed only when reverse transcriptase was included in the
reaction.
4. Discussion
In the present study, we have demonstrated that prepro-
ghrelin gene is expressed in the kidney and glomerulus. This
is the ¢rst report to show prepro-ghrelin gene expression in
any tissue other than the gastrointestinal tract and brain [9].
We have also demonstrated that the kidney contains both
ghrelin and the desacyl peptide by RP-HPLC coupled with
RIA. Since ghrelin immunoreactivities (both C-IR and N-
IR) in the kidney are more than 10 times abundant than those
in the plasma, we can conclude that ghrelin is produced in the
kidney. The C-IR in the kidney is approximately 1/140 of that
in the mouse stomach (manuscript submitted). Since ghrelin is
unstable and tends to be converted into the desacyl peptide in
vivo when administered exogenously (unpublished data), a
small amount of ghrelin produced locally may have physio-
logical functions if the receptor exists in the proximity. With
respect to N-IR/C-IR ratio, or the proportion of ghrelin in
total ghrelin immunoreactivities, the kidney and plasma have
values of 4.2% and 2.0%, respectively. These ¢ndings seem to
be consistent with a short half-life of ghrelin. The present
study also elucidates that acylation of ghrelin peptide does
occur not only in the stomach [9] but also in the kidney,
implying that molecules required for this reaction, which are
not identi¢ed yet, might be shared among di¡erent tissues.
We have further revealed the gene expression in cultured
mesangial cells and podocytes, suggesting that these cells are
the cellular components expressing prepro-ghrelin gene in the
glomerulus in vivo. Moreover, the gene of its receptor, GHS
receptor, is also expressed in the kidney. In previous reports,
GHS receptor gene expression was detected in the brain and
several peripheral tissues such as the hypothalamus, pituitary
gland, hippocampus, heart, pancreas, intestine and adipose
tissue [9,15]. The present study adds the kidney as one of
possible targets of direct ghrelin action, which should be in-
dependent of GH release [14]. Furthermore, prepro-ghrelin
gene expression is observed in ¢broblast-like NRK-49F cells.
Fibroblast accumulation and ¢brosis have been well known to
play important roles in tubulointerstitial renal diseases, which
strongly a¡ect renal function [22]. Thus, ghrelin might not
only have physiological but also pathophysiological signi¢-
cance in the kidney. Further studies on the intrarenal local-
ization of ghrelin and its receptor, and on the direct actions of
ghrelin upon the kidney and cultured renal cells are ongoing
in our laboratory.
Here, we describe the gene expression of prepro-ghrelin and
ghrelin receptor in the kidney. These ¢ndings suggest possible
roles of ghrelin in the kidney as endocrine and/or paracrine
system. The present study provides new insights into our
understanding of the physiological and clinical implications
of ghrelin.
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